Clinical Trials Logo

Waldenstrom's Macroglobulinemia clinical trials

View clinical trials related to Waldenstrom's Macroglobulinemia.

Filter by:

NCT ID: NCT00146055 Completed - Clinical trials for Myelodysplastic Syndromes

Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood

Start date: March 2000
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether a less-intensive preparative therapy followed by an allogeneic peripheral stem cell transplantation will provide an effective treatment for your disease and whether it will be associated with fewer side effects.

NCT ID: NCT00142181 Completed - Clinical trials for Lymphoplasmacytic Lymphoma

Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia

Start date: March 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and effects (good or bad) of Campath-1H antibody in the treatment of lymphoplasmacytic lymphoma.

NCT ID: NCT00142168 Terminated - Clinical trials for Waldenstrom's Macroglobulinemia

CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

Start date: September 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the number of patients with Waldenstrom's macroglobulinemia that will benefit from treatment with CC-5103 (lenalidomide) and rituximab, what the side effects are and how long the benefit will last.

NCT ID: NCT00142155 Completed - Clinical trials for Waldenstrom's Macroglobulinemia

Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia

Start date: January 2002
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if the type of Fc gamma RIIIa receptor that a particular patient's immune cells possess influences how they respond to rituximab and other monoclonal antibodies.

NCT ID: NCT00142129 Completed - Clinical trials for Lymphoplasmacytic Lymphoma

Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia

Start date: December 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate how tumors in patients with Waldenstrom's macroglobulinemia respond to treatment with bortezomib (Velcade) and to see what effects (good and bad) it has on the cancer.

NCT ID: NCT00142116 Completed - Clinical trials for Lymphoplasmacytic Lymphoma

Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia

Start date: May 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the percentage of people who can attain remission and the length of time such responses to therapy are sustained, as well as the side effects that might result from rituximab and thalidomide in people with lymphoplasmacytic lymphoma.